References
- Stocken L A, Thompson R HS. British Anti-Lewisite. 2. Dithiol compounds as antidotes for arsenic. Biochem J 1946; 40: 535–548
- Eagle H, Magnuson H J, Fleischman R. The systematic treatment of experimental arsenic poisoning (marphasen, lewisite, phenyl arsenoxide) with BAL. J Clin Invest 1946; 25: 451–466
- Tadlock C H, Aposhian H V. Protection of mice against the lethal effects of sodium arsenite by 2,3-dimercapto-1-propane-sulfonic acid and dimercaptosuccinic acid. Biochem Biophys Res Comm 1980; 94: 501–507
- Longcope W T, Luetscher J A, Wintrobe M M, Juger V. The treatment of arsenical dermatitis with preparations of BAL. J Clin Invest 1946; 25: 528–533
- Carleton A B, Peters R A, Thompson R HS. The treatment of arsenical dermatitis with dimercaptopropanol. Quart J Med 1948; 17: 49–79
- Woody N C, Kometani J T. BAL in the treatment of arsenic ingestion of children. Pediatrics 1948; 1: 372–378
- Longcope W T, Luetscher J A. The use of BAL (British Anti-Lewisite) in the treatment of the injurious effects of arsenic, mercury, and other metallic poisons. Ann Intern Med 1949; 31: 545–553
- Germuch F G, Eagle H. The efficacy of BAL (2,3-dimercaptopropanol) in the treatment of experimental lead poisoning in rabbits. J Pharm Exp Ther 1948; 92: 397–410
- Bessman S P, Reid H, Rubin M. Treatment of lead encephalopathy with calcium disodium versenate. M Ann District of Columbia 1952; 21: 312–315
- Roderer G. On the toxic effects of tetraethyl lead and its derivatives on the chrysophyte Poterioochromonas malhamensis. IV. Influence of lead antidotes and related agents. Chem-Biol Interact 1983; 46: 247–254
- Hofmann U, Segewitz G. Influence of chelation therapy on acute lead intoxication in rats. Arch Toxicol 1975; 34: 213–225
- Chisolm J J. The use of chelating agents in the treatment of acute and chronic lead intoxication in children. J Pediat 1968; 73: 1–38
- Wade J F, Burnum J F. Treatment of acute and chronic lead poisoning with disodium calcium versenate. Ann Intern Med 1955; 42: 251–259
- Rieders F, Dunnington W G, Breiger H. The efficacy of edathamil calcium disodium in the treatment of occupational lead poisoning. Indust Med 1955; 24: 195–202
- Smith H D. Lead poisoning in children and its therapy with EDTA. Indust Med 1959; 28: 148–155
- Cory-Slechta D A, Weiss B, Cox C. Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy. J Pharmacol Exp Ther 1987; 243: 804–813
- Wedeen R P, Mallik D K, Batuman V. Detection and treatment of occupational lead nephropathy. Arch Intern Med 1979; 139: 53–57
- Muijser H, Hoogendijk E MG, Hoosma J, et al. Lead exposure during demolition of a steel structure coated with lead-based paints. II. Reversible changes in the conduction velocity of the motor nerves in transiently exposed workers. Scand J Work Environ Health 1987; 13: 56–61
- Baker E L, White R F, Pothier L J, et al. Occupational lead neurotoxicity: improvement in behavioral effect after reduction of exposure. Brit J Ind Med 1985; 42: 507–516
- Cory-Slechta D A, Weiss B. Efficacy of the chelating agent Ca EDTA in reversing lead-induced changes in behavior. Neurotoxicology 1989; 10: 685–698
- Montoya-Cabrera M A, Sauceda-Garcia J M, Lopez-Martin G, et al. Niveles de plomo en ninos con hiperactividad y atencion deficiente. Repuesta a la administracion de D. penicilamina. Bol Med Hosp Infant Mex 1985; 42: 88–91
- Schutz A, Skerfving S, Ranstam J, et al. Kinetics of lead in blood after the end of occupational exposure. Scand J Work Environ Health 1987; 13: 221–231
- Schutz A, Skerfving S, Christofferson J O, Tell I. Chelatable lead versus lead in human trabecular bone and compact bone. Sei Tot Environ 1987; 61: 201–209
- Moel D I, Sachs H K, Drayton M A. Slow, natural reduction in blood lead level after chelation therapy for lead poisoning in childhood. Am J Dis Child 1986; 140: 905–908
- Graziano J H. Role of 2,3 dimercaptosuccinic acid in the treatment of heavy metal poisoning. Med Toxicol 1986; 1: 155–162
- Germain M J, Braden G L, Fitzgibbons J P. Failure of chelation therapy in lead nephropathy. Arch Intern Med 1984; 144: 2419–2420
- Markowitz M E, Rosen J F. Longitudinal assessment of bone lead (Pb) stores in Pb poisoned children by L x-ray fluorescence (LXRF). Annual Meeting. American Academy of Pediatrics, 1990, Abstract #794
- Wielopolski L, Ellis K J, Vaswani A N, et al. In vivo bone lead measurements: a rapid monitoring method for cumulative lead exposure. Am J Ind Med 1986; 9: 221–226
- Somervaille L J, Chettle D R, Scot M C, et al. In vivo tibia lead measurements as an index of cumulative exposure in occupationally exposed subjects. Br J Ind Med 1988; 45: 174–181